SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL is trending due to a significant after-hours price drop following its NHS-Galleri cancer screening trial missing its primary endpoint for statistically significant late-stage cancer detection. The community is sharply divided, with many calling the market reaction an extreme overreaction given the test's perceived utility, the company's solid financials, and its ongoing FDA approval process, while others anticipate further declines and question the test's overall effectiveness.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending following a mixed market reaction to its dual financing announcement: a proposed $100 million public stock offering and a $100 million royalty funding deal with RTW Investments. While some investors express significant concern over dilution, others view the combined capital as a strategic move to secure a robust runway for its advanced pipeline and upcoming BLA submission, enhancing long-term commercialization flexibility.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending following its recent revenue growth and the significant extension of its IBSRELA and XPHOZAH patent protection into 2042, fueling community debate on long-term value creation through increased development spending versus immediate profitability, alongside continued speculation about potential strategic partnerships.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending as a recent corporate presentation highlighted significant anticipated distribution and shelf space growth for its brands, further bolstered by positive comments from a key strategic partner regarding collaboration and market execution. While many in the community are optimistic about continued sales expansion, others express frustration over recent stock volatility and perceived management communication challenges.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is trending due to its significant all-stock merger with Valaris, poised to create a dominant offshore drilling entity with a substantial backlog and anticipated cost synergies. The community is actively discussing a potential short squeeze and a long-awaited turnaround for the company amidst robust demand in the energy sector.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is gaining significant attention amid strong rumors of a potential partnership with OpenAI to monetize ChatGPT through ads, fueling investor excitement and a desire for a short squeeze. This speculation comes as the community debates the stock's recent sharp decline, which many view as an unjustified overreaction to broader AI disruption fears, given the company's robust earnings and advanced AI ad-tech.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna (KLAR) is experiencing extreme volatility and trending heavily after its latest earnings report revealed robust revenue growth and expanding user base, especially in the US, but also a net loss driven by a significant increase in loan loss provisions. The community is sharply divided, with many calling the 'buy now, pay later' business model unsustainable and predicting further declines, while others view the sell-off as an 'overreaction' and a prime buying opportunity, citing strong underlying growth and strategic partnerships.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont is trending as its strong earnings and record free cash flow contrast sharply with a conservative 2026 outlook forecasting lower gold production and higher costs, sparking community debate about its future trajectory despite a broad surge in gold prices.

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Protara Therapeutics Inc

Protara Therapeutics is currently trending as a recent public offering has introduced volatility following positive clinical trial data for its TARA-002 compound in bladder cancer and lymphatic malformations. The community is actively debating the short-term impact of potential dilution versus the long-term potential of the company's promising pipeline and upcoming data milestones, despite strong institutional backing and bullish analyst targets.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense & Security Solutions is trending amidst surging defense spending expectations following proposed budget increases and escalating global tensions. The community is focused on recent substantial contract wins in hypersonics, unmanned systems, and defense testing, which, combined with bullish technical indicators, is fueling optimism for its established uptrend.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

YD Bio (NASDAQ:YDES) Trading Down 8.5% - What's Next?

YD Bio (NASDAQ:YDES) Trading Down 8.5% - Time to Sell...

YD Bio (NASDAQ:YDES) Shares Gap Down - Here's Why

YD Bio (NASDAQ:YDES) Shares Gap Down - Time to Sell...

True Velocity, Inc./DE (NASDAQ:YDES) Shares Down 5.5% - Should You Sell?

True Velocity, Inc./DE (NASDAQ:YDES) Shares Down 5.5% - Time to Sell...

True Velocity, Inc./DE (NASDAQ:YDES) Sees Unusually-High Trading Volume - Time to Buy?

True Velocity, Inc./DE (NASDAQ:YDES) Sees Strong Trading Volume - Should You Buy...

<ul class="summary-bullets"><li>The company also said that its Exovisse Artificial Tears have been developed in compliance with FDA mandates permitting nationwide over‑the‑counter distribution.</li><li>YD Bio now plans to conduct a small clinical trial in Taiwan to evaluate dry eye disease in collaboration with 3D Global Biotech.</li><li>The company is also advancing LSC Exosome Therapeutics through its collaboration with 3D Global Biotech for retinal and macular disorders.</li></ul>Taiwan-based biotechnology company YD Bio (YDES) said on Monday that it has reached a set of milestones that together mark its commercial entry into U.S. eye care.Following the announcement, shares of the firm traded 7% higher at the time of writing. &nbsp;The Taiwan-based company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ydesgroup.com/pressreleases/detail/23e04a99-0c62-4d1e-bd0e-ea782181d34c">said</a> that Exovisse Contact Lenses have obtained U.S. Food and Drug Administration clearance through its partner, 3D Global Biotech, confirming that the lenses are substantially equivalent to an already marketed device and can be sold in the U.S.The company also said that its Exovisse Artificial Tears have been developed in compliance with FDA mandates permitting nationwide over‑the‑counter distribution for eye hydration and dry eye comfort without individual FDA premarket approval.<h2 class="st-heading-2">Future Plans</h2>YD Bio now plans to conduct a small clinical trial in Taiwan to evaluate dry eye disease in collaboration with 3D Global Biotech and Taiwan-based contract research organization YC Biotech.The company is also advancing LSC Exosome Therapeutics through its collaboration with 3D Global Biotech for retinal and macular disorders. LSC exosome therapeutics refers to the use of exosomes derived from limbal stem cells (LSCs) for therapeutic purposes, particularly for conditions affecting the eye, like dry eye syndrome.The company said that it has enrolled its limbal stem cells and limbal stem cell exosomes in the FDA Drug Master File, establishing documentation to support future therapeutic development.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around YDES stayed within the ‘neutral’ territory while message volume remained at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:586/61;" src="data:image/png;base64,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" width="586" height="61" alt="YDES’s Sentiment Meter and Message Volume as of 12:37 p.m. ET on Nov. 24, 2025 | Source: Stocktwits"><figcaption>YDES’s Sentiment Meter and Message Volume as of 12:37 p.m. ET on Nov. 24, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/YDES">YDES stock</a> is down by 20% this year and by about 22% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pharma-bro-martin-shkreli-goes-short-on-capircor-therapeutics/cL5bQHUREQS">‘Pharma Bro’ Martin Shkreli Goes Short On Capricor Therapeutics – Stock Tumbles 17%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

YD Bio Stock Rises On Entry Into US Eye Care Segment

The Taiwan-based company said that Exovisse Contact Lenses have obtained the U.S. Food and Drug Administration’s clearance through its partner 3D Global Biotech.

Equity

Shares of YD Bio drew&nbsp;the attention of retail traders&nbsp;late Monday following the company’s announcement that&nbsp;it had completed its merger with Breeze Holdings Acquisition Corp, a special purpose acquisition company (SPAC).YD Bio’s ordinary shares and warrants began trading on the Nasdaq Global Market on Aug. 29 under the symbols YDES and YDESW, carrying forward the listing of Breeze Holdings Acquisition Corp. The SPAC’s shares, now trading as&nbsp;<a href="https://stocktwits.com/symbol/YDES">YDES</a>, have gained 11.1% so far in 2025.Breeze shareholders approved the deal at a meeting on Aug. 14.The company stated that a private investment in public equity was also closed alongside the merger. Together with cash released from Breeze’s trust account, YD Bio expects to receive more than $11.5 million to fund operations.Chairman and CEO Ethan Shen said the listing marked a milestone in the company’s transformation from a supplier of clinical trial drugs to a developer of diagnostics and therapies.&nbsp;YD Bio’s pipeline includes DNA methylation-based cancer detection tests licensed from EG BioMed, including a laboratory-developed screening test for pancreatic cancer, which is already available through EG BioMed’s certified laboratory. A monitoring test for recurrent breast cancer is expected to launch later this year.In ophthalmology, the company is advancing stem cell and exosome-based therapies with partner 3D Global Biotech to treat conditions such as dry eye syndrome, glaucoma, and corneal injury. Trials are planned in 2027 to evaluate exosome-based contact lenses and artificial tears.The company also supplies investigational drugs and ancillary materials to global pharmaceutical companies, supporting clinical trials and post-launch commercialization. Its multi-decade licensing agreements and proprietary patents provide what it calls a “significant first-mover” advantage in targeted markets.ArentFox Schiff LLP and Ogier served as legal advisers to YD Bio. I-Bankers Securities Inc. advised Breeze, with Woolery &amp; Co. PLLC as its legal counsel.On Stocktwits, retail sentiment for YD Bio was ‘extremely bullish’ amid ‘extremely high’ message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A laptop keyboard, a reflected illustrative stock graph displayed on a screen and Nasdaq logo displayed on a phone screen are seen in this illustration photo taken in Krakow, Poland on August 18, 2025.

YD Bio Stock Fuels Retail-Trader Excitement After Nasdaq Listing Through Breeze SPAC Deal

YD Bio trades under YDES following the Breeze merger, with a pipeline that spans cancer detection and eye disease therapies.

YD Bio Ltd. engages in the development of detection and therapeutic technologies. It offers cancer detection products, regenerative ophthalmology products, and exosome science. It operates through the following segments: Sales of Medical Devices and Other Related Products, Research and Development in Pancreatic Early Detection Services, and Research and Development in Sales of Contact Lenses. The company was founded on February 6, 2024 and is headquartered in Taipei, Taiwan.

YDES
YD Bio Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest YDES News

YDESYD Bio Ltd.